In our study, we retrospectively evaluated the lipocalin-2 expression immunohistochemically in sections obtained from paraffin-embedded human prostate adenocarcinoma tissue samples, investigated the role of lipocalin-2 expression in predicting treatment response to docetaxel, and evaluated whether there is a relationship between its expression levels and Gleason's grade in the patients with metastatic prostate adenocarcinoma. This evidence concerns the gene LCN2 and prostate adenocarcinoma.